JHB

Journal of Health and Biology

https://journalhb.org/

SPBH

Review article:

Neurochemical and Neurocircuitry Perspectives on the Science of Addiction

Othman Ali Othman*, Youssef Yasser Mokhtar.

Chemistry Department (Biochemistry Division)-Faculty of Science- Minia University- 61519, ElMinia –Egypt.

***Corresponding Authors: Othman Ali Othman -** Chemistry Department (Biochemistry Division), Faculty of Science, Minia University, 61519 El-Minia, Egypt- (Tel: 00201099632168)

Email: osman.mouftah@mu.edu.eg-ORCID:http://orcid.org/0000-0003-4061-6929

DOI: 10.71428/JHB.2025.0103

ABSTRACT

Addiction is a complex disorder affecting millions worldwide, presenting significant public health and research challenges. This review examines the biochemical and neuroscientific mechanisms underlying addiction, emphasizing the roles of neurotransmitters such as dopamine, glutamate, GABA, serotonin, and endocannabinoids in reward processing and compulsive drug-seeking behavior.

The biochemical effects of addictive substances, including alcohol, opioids, stimulants, nicotine, and cannabis, are explored, highlighting their neurotoxic impact and cognitive impairments. The review also discusses genetic and epigenetic influences, illustrating gene-environment interactions that contribute to addiction susceptibility. Treatment approaches, both pharmacological and non-pharmacological, are examined. Medications like methadone, buprenorphine, and N-acetylcysteine target neurotransmitter systems, while therapies such as cognitive-behavioral therapy (CBT) and transcranial magnetic stimulation (TMS) offer alternative interventions. Emerging treatments, including gene therapy and AI-driven predictive models, suggest a promising future in addiction treatment.

This review underscores the necessity of a multidisciplinary approach to addiction research and treatment. Understanding addiction's neurobiological foundations can lead to innovative therapeutic strategies, ultimately improving outcomes for those affected by substance use disorders.

Keywords: Addiction neurobiology, TMS, GABA, CBT.

INTRODUCTION

Addiction is a chronic, relapsing disorder characterized by compulsive drug-seeking behavior despite adverse consequences, clinically defined by the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5) through 11 criteria including tolerance, withdrawal, and loss of behavioral control [1] With over 35 million individuals affected globally, substance use disorders impose staggering socioeconomic burdens and healthcare costs, underscoring the urgent need for mechanistic insights and innovative treatments [2].

Historically, addiction was mischaracterized as a moral failing or lack of willpower. However, paradigm-shifting advances in neuroscience have redefined it as a brain disorder involving persistent neuroadaptations in reward (mesolimbic dopamine system), stress (extended amygdala), and executive control (prefrontal cortex) circuits [3]. This transition from behavioral to biological frameworks stems from seminal discoveries: Neuroimaging studies mapping structural and functional changes in addicted brains [4]. Molecular evidence of drug-

Received: February 2, 2024. Accepted: April 5, 2025. Published: April 28, 2025

induced synaptic plasticity [3]. Genetic and epigenetic vulnerability factors [5].

Central to addiction pathology is the dopaminergic mesolimbic pathway (Figure 1), comprising projections from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and prefrontal cortex (PFC) [6]. Addictive substances hijack this evolutionarily conserved reward system through distinct mechanisms:

Psychostimulants (e.g., cocaine) block dopamine reuptake, prolonging synaptic signaling [7]. **Opioids** disinhibit VTA dopamine neurons via GABAergic interneuron suppression [8]. **Alcohol** and **sedatives** modulate glutamate and GABA receptor kinetics, disrupting excitation-inhibition balance [9]. Chronic exposure triggers maladaptive neuroplasticity, including D2 receptor own regulation in the NAc [10], dendritic spine remodeling in the PFC [11], and epigenetic reprogramming of stress-related genes [12]. These changes perpetuate a vicious cycle of craving, compulsive use, and relapse, even after prolonged abstinence [3]. This review synthesizes contemporary insights into addiction's neurobiology, with three key objectives:

Elucidate the mechanistic underpinnings of neurotransmitter dysregulation (dopamine, glutamate, endocannabinoids) [6]

Decipher substance-specific neuroadaptations (alcohol, opioids, stimulants) [13]

Evaluate therapeutic strategies, from pharmacotherapy (e.g., buprenorphine [14]) to neuromodulation (e.g., transcranial magnetic stimulation [15])

By bridging preclinical and clinical research, we aim to highlight translational opportunities for this multifaceted disorder, emphasizing emerging technologies like CRISPR-based interventions [16] and artificial intelligence-driven personalized medicine [17].



Functional domain	Circuit	Brain region	Neuro-transmitter
Binge/ intoxication	1	VTA	Glutamate
	2	VTA	GABA
	3	dStr	Dopamine
	4	dStr	Glutamate
Withdrawal/ negative affect	5	VTA	CRF
	6	Amyg(Ce)	CRF
	7	BNST	Noravrenaline
	8	NAc	Dynorphin
	9	Habenula	ACh
	10	Amyg(Ce)	NPY
	11	Amyg(Ce)	EC
Preoccupation/ anticipation	12	PFC	Glutamate
	13	PFC	GABA
	14	Hippo	Glutamate
	15	Amyg(B)	Glutamate
	16	BNST	CRF
	17	BNST	Norepinephrine
	18	Insula	CRF

Figure 1 Brain regions involved in substance use and addiction [4]

Neurotransmitter Systems in Addiction

The neurochemical basis of addiction involves dysregulation of key neurotransmitter systems, particularly dopamine (DA), glutamate, and γ-aminobutyric acid (GABA), which collectively modulate reward processing, learning, and behavioral control [18].

Dopamine and Reward Processing

Dopaminergic neurons originating in the ventral tegmental area (VTA) project to the nucleus accumbens (NAc) and prefrontal cortex (PFC), forming the mesolimbic and mesocortical pathways that are critical for reinforcement learning [19]. Acute drug exposure produces substance-specific effects on DA signaling: psychostimulants such as cocaine block dopamine transporters (DAT), thereby increasing extracellular DA concentrations [7], while opioids disinhibit VTA DA neurons through suppression of GABAergic interneurons [8]. Chronic exposure leads to persistent neuroadaptations, including downregulation of D2 receptors in the NAc and blunted DA signaling during withdrawal, which collectively reduce sensitivity to natural rewards while promoting compulsive drug-seeking behavior [3].

Glutamate-GABA Imbalance

Addictive substances disrupt the delicate equilibrium between glutamatergic excitation and GABAergic inhibition. Chronic cocaine use, for example, enhances glutamatergic transmission through increased AMPA receptor trafficking in the NAc, thereby strengthening drug-cue associations [20], whereas alcohol suppresses NMDA receptor function, impairing synaptic plasticity [21]. Concurrently, substances like benzodiazepines and alcohol acutely potentiate $GABA_A$ receptor activity but induce receptor desensitization with prolonged use [9], while reduced $GABA_B$ receptor tone contributes to the hyperexcitability characteristic of withdrawal states [22].

Modulatory Systems

Beyond the primary excitatory and inhibitory systems, serotonin (5-HT) plays a crucial role in modulating mood and impulsivity, with clinical evidence linking low 5-HT activity to increased relapse vulnerability [23]. Similarly, the endocannabinoid system, through mediators such as anandamide, acting on CB1 receptors, exerts fine-tuned regulation over dopamine (DA) release and reward sensitivity [24].

Dopamine Receptors

The D1-like receptor family (D1/D5), which is G_s-coupled and enhances cAMP signaling, promotes reward-related learning. D2-like receptors (D2/D3/D4), being G_i-coupled and inhibitory to cAMP production, modulate aversion and habit formation. Chronic drug exposure preferentially reduces D2 receptor availability, impairing top-down inhibitory control [25].

Ionotropic Receptor Modifications

Key ionotropic receptors undergo substance-specific adaptations: NMDA receptors mediate synaptic plasticity and long-term potentiation in response to alcohol and ketamine [26]; AMPA receptors facilitate drug-cue associations in stimulant addiction [27]; and $GABA_A$ receptors mediate the sedative effects of benzodiazepines while contributing to withdrawal pathophysiology [28].

G-Protein Coupled Receptors

The μ-opioid receptors (MOR) mediate both the euphoric and analgesic effects of opioids like heroin and fentanyl [29], while CB1 cannabinoid receptors in the NAc regulate DA release and contribute to the rewarding properties of THC [30].

cAMP-Dependent Pathways

Acute drug exposure activates cAMP/protein kinase A (PKA) signaling, leading to cAMP

response element-binding protein (CREB) phosphorylation and subsequent dynorphin release, which underlies the dysphoric state of withdrawal [31]. Chronic use triggers compensatory downregulation of this pathway, resulting in tolerance and dose escalation [3].

Growth-Related Cascades

The MAPK/ERK pathway is activated by cocaine in the NAc, promoting long-term synaptic potentiation [32], while the mechanistic target of rapamycin (mTOR) mediates drug-induced dendritic spine growth in the PFC, thereby sustaining addictive behaviors [33].

Biochemical Impact of Common Addictive Substances

Alcohol

Alcohol primarily modulates $GABA_A$ receptors, enhancing inhibitory neurotransmission, and suppresses NMDA receptor activity, leading to sedative and cognitive-impairing effects (21). Chronic use downregulates GABA receptors and upregulates glutamatergic signaling, contributing to hyperexcitability during withdrawal (3). Alcohol also increases dopamine release in the nucleus accumbens (NAc), reinforcing its rewarding properties (34). Long-term effects include neuroinflammation, oxidative stress, and hippocampal damage due to acetaldehyde toxicity (35). Genetic polymorphisms in alcohol-metabolizing enzymes (e.g., ALDH2) influence susceptibility to dependence (36).

Opioids

Opioids bind **mu-opioid receptors (MORs)**, inhibiting GABAergic interneurons in the ventral tegmental area (VTA), which disinhibits dopamine neurons and increases **dopamine** release in the NAc (37). Chronic use leads to MOR desensitization, upregulation of **cAMP/PKA** signaling, and increased dynorphin expression, exacerbating withdrawal dysphoria (31). Long-term neuroadaptations include prefrontal cortex (PFC) dysfunction and heightened stress responses via **CRF** in the amygdala (38). The opioid epidemic underscores the need for therapies like buprenorphine (partial MOR agonist) and naltrexone (MOR antagonist) (39).

Cocaine and Stimulants

Cocaine and amphetamines increase synaptic dopamine by blocking DAT or reversing transporter activity (13). They also elevate norepinephrine and serotonin, contributing to arousal and euphoria (40). Chronic use reduces D2 receptor density, blunts dopamine signaling, and induces glutamatergic hyperactivity in the NAc and PFC, driving compulsive use (5). Methamphetamine causes pronounced neurotoxicity via oxidative stress and dopamine terminal degeneration (41). Pharmacological interventions like modafinil (dopamine enhancer) and N-acetylcysteine (glutamate modulator) show promise (42).

Nicotine

Nicotine activates nicotinic acetylcholine receptors (nAChRs), particularly α4β2 subtypes, increasing dopamine release in the NAc and enhancing cognition via glutamate and GABA modulation (43). Chronic use upregulates nAChRs, perpetuating dependence (44). Withdrawal symptoms (e.g., irritability, cognitive deficits) are linked to reduced PFC function (45). Epigenetic modifications (e.g., DNA methylation) contribute to long-term addiction vulnerability (12). Therapies include varenicline (nAChR partial agonist) and bupropion (dopamine/norepinephrine reuptake inhibitor) (46).

Cannabis and Synthetic Cannabinoids

Δ9-THC, the primary psychoactive compound in cannabis, binds CB1 receptors, disinhibiting VTA dopamine neurons and amplifying reward (47). Chronic use downregulates CB1 receptors and impairs hippocampal-dependent memory (48). Synthetic cannabinoids (e.g., Spice) exhibit higher

potency and unpredictable effects, posing severe public health risks (49). Cannabidiol (CBD), a non-psychoactive cannabinoid, shows therapeutic potential for reducing cravings and anxiety (50).

The neurobiological underpinnings of addiction involve persistent dysregulation of key brain circuits, particularly the mesolimbic dopamine pathway, along with maladaptive changes in the prefrontal cortex (PFC), amygdala, and hippocampus. These alterations drive compulsive drug-seeking, cue-induced relapse, and heightened stress sensitivity, perpetuating the cycle of addiction.

Addiction and Brain Circuitry

Mesolimbic Dopamine Pathway (VTA–NAc–PFC):

The ventral tegmental area (VTA) and nucleus accumbens (NAc) form the core of the brain's reward circuitry. Natural rewards (e.g., food, social interaction) and drugs of abuse both increase dopamine release in the NAc, reinforcing behavior (51). However, addictive substances induce supraphysiological dopamine surges—cocaine blocks dopamine reuptake via the dopamine transporter (DAT), while opioids disinhibit VTA dopamine neurons by suppressing GABAergic interneurons (13). Chronic drug exposure leads to hypodopaminergic states, characterized by reduced D2 receptor availability and blunted reward sensitivity, which drive compulsive drug use to restore dopamine levels (3).

The prefrontal cortex (PFC) exerts top-down control over reward-seeking behavior. Addiction weakens PFC function, impairing impulse inhibition and decision-making. Neuroimaging studies reveal reduced gray matter volume and disrupted connectivity in the PFC of addicted individuals, correlating with poor treatment outcomes (11).

.



Figure 2. A map of the brain's reward center (52)

Amygdala and Hippocampus in Relapse

The amygdala mediates cue-triggered cravings by associating drug-related stimuli with reward. Drug exposure enhances glutamatergic input from the amygdala to the NAc, strengthening maladaptive memories (53). Chronic use also upregulates corticotropin-releasing factor (CRF) in the amygdala, linking stress to relapse vulnerability (38).

The hippocampus encodes contextual drug memories, such as environments where substance use occurred (54). Addictive drugs impair hippocampal neurogenesis and synaptic plasticity, contributing to persistent relapse risk even after prolonged abstinence (55).

Neuroplasticity and Stress-Induced Relapse Repeated drug use induces **long-term synaptic plasticity** in the mesolimbic pathway. For example, cocaine increases dendritic spine density in NAc medium spiny neurons, enhancing excitatory input (56). These structural changes are regulated by mTOR and ERK/MAPK signaling, which promote the translation of addiction-related proteins (57). Stress exacerbates relapse via the hypothalamic-pituitary-adrenal (HPA) axis and orexin system in the hypothalamus (38). Withdrawal-induced stress responses further reduce PFC control over reward circuits, creating a vicious cycle of craving and drug-seeking (3).



Figure 3. mTORC1 Signaling in Drug Addiction: Activation by Drugs of Abuse and Role in Neuroadaptations Underlying Drug Seeking and Relapse [55].

Received: February 2, 2024. Accepted: April 5, 2025. Published: April 28, 2025

Genetic and Environmental Factors in Addiction Susceptibility

Addiction arises from complex interactions between genetic predisposition and environmental exposures, with gene-environment (GxE) interactions playing a pivotal role in modulating risk. Twin and family studies estimate that 40–60% of addiction vulnerability is heritable, though the specific genetic contributions vary across substances (58). Key candidate genes influence dopamine signaling, stress responses, and executive function, while environmental factors such as early-life trauma and socioeconomic stress amplify risk in genetically susceptible individuals.

Genetic Predisposition

Polymorphisms in the dopamine D2 receptor gene (DRD2) are among the most well-replicated genetic risk factors for addiction. The Taq1A A1 allele of *DRD2* is associated with reduced D2 receptor density in the striatum, blunted reward sensitivity, and increased propensity for substance use. Similarly, variants in catechol-O-methyl transferees (COMT), which regulates dopamine catabolism, modulate prefrontal cortical function. The COMT Val158Met polymorphism alters enzyme activity, with the Met allele linked to heightened stress reactivity and poorer cognitive control—traits that may predispose to compulsive drug use (59).

Genes involved in stress and serotonin signaling further modulate addiction vulnerability. The short allele of the serotonin transporter-linked polymorphic region (5-HTTLPR) in *SLC6A4* interacts with childhood adversity to increase the risk of alcohol and cocaine dependence (60). Likewise, polymorphisms in brain-derived neurotrophic factor (BDNF), critical for synaptic plasticity, are associated with altered reward processing and withdrawal severity (61).

Environmental Influences

Early-life stress, including abuse or neglect, induces lasting dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, enhancing sensitivity to drugs of abuse (62). Social determinants such as poverty, peer influence, and drug availability further compound risk, particularly during adolescence when neural circuits are still maturing (63). Notably, GxE interactions illustrate how environmental exposures unmask genetic vulnerabilities. For example, carriers of the *DRD2* A1 allele exhibit heightened susceptibility to peer-influenced substance use, while the *5-HTTLPR* short allele amplifies stress-induced craving (64).

Epigenetic Mechanisms

Chronic drug exposure and stress induce epigenetic modifications that stabilize addiction-related behaviors. DNA methylation of the *FosB* gene in the NAc promotes persistent synaptic remodeling and drug-seeking (12), while histone acetylation alterations at *BDNF* loci impair stress resilience (61). These modifications may explain the transgenerational transmission of addiction risk and offer targets for novel therapies, such as histone deacetylase (HDAC) inhibitors (16).

Treatment and Future Directions in Addiction Therapy

The treatment of substance use disorders has evolved to target both the neurobiological underpinnings and behavioral manifestations of addiction. Current approaches integrate pharmacological interventions with psychosocial therapies, while emerging technologies promise more personalized and effective treatments.

Pharmacological Treatments

Medications for addiction primarily aim to normalize dysregulated neurotransmitter systems. For opioid use disorder, methadone (a full mu-opioid receptor agonist) and buprenorphine (a partial agonist) reduce withdrawal symptoms and cravings while minimizing euphoric effects

(14). Naltrexone, an opioid antagonist, blocks the rewarding effects of both opioids and alcohol and is particularly effective when combined with behavioral therapy (65).

In alcohol dependence, acamprosate modulates glutamatergic hyperactivity, while disulfiram produces aversive effects by inhibiting aldehyde dehydrogenase (66). For stimulant use disorders, N-acetylcysteine (NAC) has shown promise in restoring glutamate homeostasis in the nucleus accumbens, thereby reducing cue-induced craving (42). Selective serotonin reuptake inhibitors (SSRIs) are sometimes used off-label, particularly in cases with comorbid depression, though their efficacy as standalone treatments remains limited (67).

Non-Pharmacological Interventions

Cognitive-behavioral therapy (CBT) remains a cornerstone of addiction treatment, helping patients identify triggers, develop coping strategies, and modify maladaptive thought patterns (68). Contingency management, which provides tangible rewards for drug-free behaviors, has demonstrated particular efficacy in stimulant use disorders (69).

Neuromodulator techniques such as transcranial magnetic stimulation (TMS) target the prefrontal cortex to reduce cravings and improve cognitive control in nicotine and cocaine dependence (15). Mindfulness-based interventions, though less studied, show potential in reducing stress reactivity and preventing relapse by enhancing emotional regulation.

Emerging Approaches

Recent advances in biotechnology have opened new avenues for addiction treatment. Gene therapy approaches, including CRISPR-based editing of addiction-related genes (e.g., *FosB*, *DRD2*), are under preclinical investigation. Viral vector-mediated delivery of neuroprotective factors (e.g., GDNF) to the mesolimbic pathway has shown promise in animal models of opioid and alcohol dependence (70). Artificial intelligence (**AI**) is increasingly being leveraged to predict treatment outcomes and optimize therapeutic strategies. Machine learning algorithms can analyze large datasets—including genetic, neuroimaging, and behavioral markers—to identify individuals at high risk of relapse and match them to tailored interventions (17,71). Digital therapeutics, such as smartphone apps for real-time craving management, represent another promising frontier in addiction care (72).

Conclusion

Addiction represents one of the most complex challenges in modern medicine, characterized by persistent neurobiological adaptations that drive compulsive drug-seeking despite adverse consequences (3). The transition from voluntary use to addiction reflects profound changes in reward, stress, and executive control systems, mediated by dysregulation of dopamine, glutamate, and other neurotransmitter pathways (12). While the chronic and relapsing nature of addiction presents significant treatment hurdles (39), advances in neuroscience have illuminated key molecular and circuit-level mechanisms underlying the disorder (2).

The integration of pharmacological and behavioral therapies—such as opioid maintenance medications (e.g., methadone, buprenorphine [14]), glutamate modulators (e.g., N-acetylcysteine [42]), and cognitive-behavioral interventions (68)—has improved clinical outcomes, yet relapse rates remain high (30). Emerging approaches, including neuromodulation (e.g., TMS [15]), epigenetic therapies (e.g., HDAC inhibitors [16]), and AI-driven personalized medicine (17), offer promising avenues for more effective and targeted treatments. Crucially, future research must bridge the gap between preclinical findings and clinical applications, particularly in addressing individual variability in treatment response (2). As our understanding of addiction neurobiology deepens

(6), so too does the potential for innovative solutions. By combining mechanistic insights with technological advances (17), the field is moving toward a future where addiction can be managed with greater precision and efficacy, ultimately reducing its devastating personal and societal impact (39).

Conflict of interest: NIL

Funding: NIL

REFERENCES

1. Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc.; 2013. xliv, 947 p. (Diagnostic and statistical manual of mental disorders: DSM-5™, 5th ed).
2. Volkow ND, Koob GF, McLellan AT. Neurobiologic Advances from the Brain Disease Model of Addiction. Engl J Med.2016 Jan 28;374(4):363–71.
3. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760–73.
4. Hayes A, Herlinger K, Paterson L, Lingford-Hughes A. The neurobiology of substance use and addiction: evidence from neuroimaging and relevance to treatment. BJPsych Adv. 2020 Nov;26(6):367–78.
5. Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues. NeuroImage. 2008 Feb 1;39(3):1266–73.
6. Volkow ND, Michaelides M, Baler R. The Neuroscience of Drug Reward and Addiction. Physiol Rev. 2019 Oct 1;99(4):2115–40.
7. Ferris MJ, Calipari ES, Mateo Y, Melchior JR, Roberts DC, Jones SR. Cocaine Self-Administration Produces Pharmacodynamic Tolerance: Differential Effects on the Potency of Dopamine Transporter Blockers, Releasers, and Methylphenidate. Neuropsychopharmacology. 2012 Jun;37(7):1708–16.
8. Wise RA, Koob GF. The development and maintenance of drug addiction. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014 Jan;39(2):254–62.
9. Nutt DJ, Malizia AL. New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001 Nov;179(5):390–6.
10. Volkow ND, Wang GJ, Tomasi D, Baler RD. The addictive dimensionality of obesity. Biol Psychiatry. 2013 May 1;73(9):811–8.
11. Goldstein RZ, Craig AD (Bud), Bechara A, Garavan H, Childress AR, Paulus MP, et al. The Neurocircuitry of Impaired Insight in Drug Addiction. Trends Cogn Sci. 2009 Sep 1;13(9):372–80.
12. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014 Jan 1;76:259–68.
13. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol. 2005 Apr 1;75(6):406–33.
14. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-Assisted Therapies Tackling the Opioid-Overdose Epidemic. N Engl J Med. 2014 May 29; 370(22):2063–6.
15. Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, et al. Smoking Cessation Induced by Deep Repetitive Transcranial Magnetic Stimulation of the Prefrontal and Insular Cortices: A Prospective, Randomized Controlled Trial. Biol Psychiatry. 2014 Nov 1;76(9):742–9.

16. Hamilton PJ, Nestler EJ. Epigenetics and addiction. Curr Opin Neurobiol. 2019 Dec 1; 59: 128–36.
17. Yip SW, Scheinost D, Potenza MN, Carroll KM. Connectome-Based Prediction of Cocaine Abstinence.Am J Psychiatry.2019 Feb;176(2):156–64.
18. ResearchGate [Internet]. [cited 2025 Feb 7]. Biochemical Basis of Neuropharmacology (8th Edition). J. R. Cooper, F. E. Bloom and R. H. Roth. Oxford University Press: Oxford, 2002. ISBN 0-19-514007-9.
19. Volkow ND, Morales M. The Brain on Drugs: From Reward to Addiction. Cell. 2015 Aug 13;162(4):712–25
20. Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol. 2010 Sep;21(5–6):514.
21. Lovinger DM, White G, Weight FF. Ethanol Inhibits NMDA-Activated Ion Current in Hippocampal Neurons. Science. 1989 Mar 31;243(4899):1721–4.
22. Ciranna L, Licata F, Li Volsi G, Santangelo F. Role of GABAA and GABAB receptors in GABA-induced inhibition of rat red nucleus neurons. Neurosci Lett. 2003 May 8;341(3):221–4.
23. Lovinger DM. Serotonin's Role in Alcohol's Effects on the Brain. Alcohol Health Res World. 1997;21(2):114–20.
24. Spanagel R. Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions. Dialogues Clin Neurosci. 2020 Sep 30;22(3):241–50.
25. Team N editorial. NeuroLaunch.com. 2024 [cited 2025 Feb 12]. Dopamine Receptors: Function, Location, and Impact on Brain Chemistry. Available from: https://neurolaunch.com/dopamine-receptor/
26. Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults. Drug Alcohol Depend. 2015 Nov 1;156:243–53.
27. Scofield MD, Heinsbroek JA, Gipson CD, Kupchik YM, Spencer S, Smith ACW, et al. The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis. Pharmacol Rev. 2016 Jul 1;68(3):816–71.
28. Lobo IA, Harris RA. GABAA receptors and alcohol. Pharmacol Biochem Behav. 2008 Jul;90(1):90–4.
29. Pasternak GW, Pan YX. Mu Opioids and Their Receptors: Evolution of a Concept. Pharmacol Rev. 2013 Oct 1;65(4):1257–317.
30. Pertwee RG. Endocannabinoids and Their Pharmacological Actions. In: Pertwee RG, editor. Endocannabinoids [Internet]. Cham: Springer International Publishing; 2015 [cited 2025 Feb 12]. p. 1–37. Available from: https://doi.org/10.1007/978-3-319-20825-1_1
31. Williams JT, Ingram SL, Henderson G, Chavkin C, Zastrow M von, Schulz S, et al. Regulation of μ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Pharmacol Rev. 2013 Jan 1;65(1):223–54
32. Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004 Mar;5(3):173–83.
33. Bailey J, Ma D, Szumlinski KK. Rapamycin attenuates the expression of cocaine-induced place preference and behavioral sensitization. Addict Biol. 2012;17(2):248–58.
34. Weiss F, Porrino LJ. Behavioral Neurobiology of Alcohol Addiction:

Recent Advances and Challenges. J Neurosci. 2002 May 1;22(9):3332–7.

35. Wu D, Cederbaum AI. Alcohol, Oxidative Stress, and Free Radical Damage. Alcohol Res Health. 2003;27(4):277–84.
36. Hurley TD, Edenberg HJ. Genes Encoding Enzymes Involved in Ethanol Metabolism. Alcohol Res Curr Rev. 2012;34(3):339–44.
37. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend. 1998 Jun 1;51(1):13–22.
38. Koob, G, Kreek MJ. Stress, Dysregulation of Drug Reward Pathways, and the Transition to Drug Dependence. Am J Psychiatry. 2007 Aug;164(8):1149–59.
39. Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA Psychiatry. 2019 Feb 1;76(2):208–16.
40. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32–41.
41. Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev. 2009 May 1;60(2):379–407.
42. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders. CNS Drugs. 2014 Feb 1;28(2):95–106.
43. Changeux JP. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci. 2010 Jun;11(6):389–401.
44. Benowitz NL. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev Pharmacol Toxicol. 2009 Feb 10;49(Volume 49, 2009):57–71.
45. Hughes JR. Effects of Abstinence From Tobacco: Valid Symptoms and Time Course. Nicotine Tob Res. 2007 Mar 1;9(3):315–27.
46. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis - Cahill, K - 2013 | Cochrane Library. [cited 2025 Feb 27];
47. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.
48. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry. 2016 Mar 1;73(3):292–7.
49. Winstock AR, Barratt MJ. Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend. 2013 Jul 1;131(1):106–11
50. Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, et al. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019 Nov;176(11):911–22.
51. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev. 1998 Dec 1;28(3):309–69.
52. The Brain in Recovery [Internet]. Recovery Research Institute. 2017 [cited 2025 May 14]. Available from:

https://www.recoveryanswers.org/recovery-101/brain-in-recovery/

53. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005 Nov;8(11):1481–9.
54. Hyman SE, Malenka RC, Nestler EJ. NEURAL MECHANISMS OF ADDICTION: The Role of Reward-Related Learning and Memory. Annu Rev Neurosci. 2006 Jul 21;29(Volume 29, 2006):565–98.
55. Noonan MA, Bulin SE, Fuller DC, Eisch AJ. Reduction of Adult Hippocampal Neurogenesis Confers Vulnerability in an Animal Model of Cocaine Addiction. J Neurosci. 2010 Jan 6;30(1):304–15.
56. Neasta J, Barak S, Hamida SB, Ron D. mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse. J Neurochem. 2014 Jul;130(2):172–84.
57. Day JJ, Childs D, Guzman-Karlsson MC, Kibe M, Moulden J, Song E, et al. DNA methylation regulates associative reward learning. Nat Neurosci. 2013 Oct;16(10):1445–52.
58. Kendler KS, Prescott CA, Myers J, Neale MC. The Structure of Genetic and Environmental Risk Factors for Common Psychiatric and Substance Use Disorders in Men and Women. Arch Gen Psychiatry. 2003 Sep 1;60(9):929–37.
59. Faraone SV, Spencer TJ, Madras BK, Zhang-James Y, Biederman J. Functional effects of dopamine transporter gene genotypes on in vivo dopamine transporter functioning: A meta-analysis. Mol Psychiatry. 2014;19(8):880–9.
60. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene. Science. 2003 Jul 18;301(5631):386–9.
61. Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting Epigenetic Influence of Early-Life Adversity on the BDNF Gene. Biol Psychiatry. 2009 May 1;65(9):760–9.
62. The enduring effects of abuse and related adverse experiences in childhood | European Archives of Psychiatry and Clinical Neuroscience [Internet]. [cited 2025 Mar 4].
63. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Drug Abuse and Dependence in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007 May 1;64(5):566–76.
64. Brody GH, Chen Y fu, Beach SRH, Kogan SM, Yu T, DiClemente RJ, et al. Differential sensitivity to prevention programming: A dopaminergic polymorphism-enhanced prevention effect on protective parenting and adolescent substance use. Health Psychol. 2014;33(2):182–91.
65. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study: A Randomized Controlled Trial. JAMA. 2006 May 3;295(17):2003–17.
66. Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res. 2006 Aug 1;40(5):383–93.
67. Lin SH, Lee LT, Yang YK. Serotonin and Mental Disorders: A Concise Review on

Molecular Neuroimaging Evidence. Clin Psychopharmacol Neurosci. 2014 Dec;12(3):196–202.

68. McHugh RK, Hearon BA, Otto MW. Cognitive Behavioral Therapy for Substance Use Disorders.Psychiatr Clin North Am.2010 Sep1;33(3):511–25.
69. Stitzer M, Petry N. Contingency Management for Treatment of Substance Abuse. Annu Rev Clin Psychol. 2006 Apr 27;2(Volume 2, 2006):411–34.
70. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. The Lancet. 2007 Jun 23;369(9579):2097–105.
71. Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, et al. A Smartphone Application to Support Recovery From Alcoholism: A Randomized Clinical Trial. JAMA Psychiatry. 2014 May 1;71(5):566–72.